Keywords: AstraZeneca, Evotec, MedImmune, Metabolic disease, Licensing, Crestor patent ruling, US, Teva, Mylan

AstraZeneca unit in 260 million-euro metabolic disease alliance with Evotec; disappointing Crestor patent ruling

Article | 16 December 2010

Print This

Germany’s Evotec AG (FSE: EVT), via its subsidiary Develogen AG, has entered into a license and collaboration agreement ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in